All News
Updates in Psoriatic Arthritis at EULAR 2022
At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.
Read Article
#EULAR2022 Updated ANCA Vasculitis Recommendations
⭐️Incorporates PEXIVAS and ADVOCATE findings
⭐️EGPA guidelines
⭐️PJP PPx recommendations
https://t.co/CnMnxTlB1D
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
No longer a "seronegative" disease?
Serological collagen biomarkers (degradation markers of type I and VI collagen) can differentiate PsO pts from PsA.
Potential biomarkers of MSK involvement?
@RheumNow #EULAR2022 ABST#OP0031 https://t.co/vS6mD5PUxw
Robert B Chao, MD doctorRBC ( View Tweet)
6 psoriatic disease specific risk factors associated with incident cardiovascular events in PsA/PsO patients: PsO area, TJC, SJC, HAQ score, ESR, daily use of NSAIDs
@RheumNow #EULAR2022 #ABSTOP0030
Robert B Chao, MD doctorRBC ( View Tweet)
NORD-STAR substudy of coagulation and fibrinolytic parameters:
〽️Impairement in eRA
⚡️Biologic parameters restored by ttmt.
Effect seemed ▶️ with Biologic vs. MTX + GCs
❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn
Aurelie Najm AurelieRheumo ( View Tweet)
🚨 Depression = major comorbidity!
DANBIO register 10000+ patients:
❗️10% prescription antidepressants💊
❗️Cumulative mortality ⬆️ w/ OR>6
❗️Particularly in age group <55
#OP0067 #EULAR2022 @RheumNow https://t.co/le8VWBFjPK
Aurelie Najm AurelieRheumo ( View Tweet)
Silverio-Antonio et al. Predictors of ILD development in MCTD. Older age at diagnosis (OR 1.1) and lymphadenopathy at presentation (OR 19.65)! predictors @RheumNow #EULAR2022 POS0901 https://t.co/IJ8Vcaga8o
Richard Conway RichardPAConway ( View Tweet)
Continue with PJP prophylaxis during the 6 months of induction Rx and until B cells repleted and if prednisone > = 20 mg/day #EULAR2022 AAV reccs @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ
Richard Conway RichardPAConway ( View Tweet)
Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t
Janet Pope Janetbirdope ( View Tweet)
Norwich regimen of steroids for GCA @cmukhtyar et al. Bespoke regime starting at 1mg/kg tapered over 100 weeks. Drug-free relapse free survival 82% at 100 weeks, 69% 150 weeks. @RheumNow #EULAR2022 POS0793 https://t.co/b5smCqCkgg
Richard Conway RichardPAConway ( View Tweet)
Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control.
Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable?
POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
David Liew drdavidliew ( View Tweet)
Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by pt factors - pt global and pain, skin, joints, CRP, function drove the data. Ask pt and treat what is treatable.
#OP0025 @eular @RheumNow https://t.co/x4T6sPEi8o
Janet Pope Janetbirdope ( View Tweet)
Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and TNFi ⬇️risk and poor HAQ⬆️ risk. #OP0030 @RheumNow @eular_org Too small events, lipids often absent and spanning 30+ yrs.
Janet Pope Janetbirdope ( View Tweet)
#EULAR OP0072: SMILE: Self-Management Individualised Learning Environment for RA
😀5 modules, with 3-4 more planned in 2022
😀Learning objectives
😀Plan to target resources to questionnaire
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Behcet disease:
RCT Topical Tacrolimus for mouth ulcers in 40+pts
↘️VAS 2 wks & 3mo
↘️ Number of ulcers
↘️ Ulcer size and duration
↘️ Ulcer severity score
#OP0046 #EULAR2022 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA
as expected:
↘️disease activity
↘️pain and function
↘️QoL
at 14 wks
no new safety alerts https://t.co/2efpx7Mi6i
Aurelie Najm AurelieRheumo ( View Tweet)
AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest.
German GESPIC AxPsA cohort:
*More frequently 🚺
*Less frequently B27+
*20% isolated Ax involvement
@Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J
Aurelie Najm AurelieRheumo ( View Tweet)
Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq
Links:
Richard Conway RichardPAConway ( View Tweet)